• 提示：詳情請下載說明書。

• 產(chǎn)品描述： Voreloxin hydrochloride is a potent inhibitor of Topoisomerase II with broad-spectrum anti-tumor activity

• 靶點： Topoisomerase;Apoptosis;Apoptosis;?Topoisomerase

• 體內(nèi)研究：
  Voreloxin (50 mg/kg i.p.) shows potent antitumor activity in mice implanted with P388 leukemia cells.Voreloxin (25 mg/kg i.v.) demonstrates strong tumor growth inhibition in 10 of 11 solid tumor (ovarian, breast, melanoma, gastric, colon, and lung) xenograft models, 2 hematologic tumor xenograft models, 3 multidrug resistant tumor models and 3 murine syngeneic tumor models (Colon 26, M5076 Ovarian Sarcoma, Lewis Lung carcinoma).

• 細(xì)胞實驗： Cell lines: P388 leukemia cells. Concentrations: about 10 μg/mL. Incubation Time: 72 hours. Method: Cells are seed in a 96-well microtiter plate (0.1 mL/well), preincubated for 24 h except for P388 cells, and incubated with various concentrations of a test compound in the 5% CO2 incubator at 37℃ for 72 h. Then, 0.02 mL MTT solution (5 mg/mL) is added in each well, and a further 4 h cells culturing is carried out. The medium is removed and 0.2 mL of DMSO is added in each well to dissolve the formed formazan. The absorbance is measured using Multiskan Bichromatic.

• 動物實驗： Animal Models: Mice implanted with P388 leukemia cells. Dosages: about 50 mg/kg. Administration: i.p.

• 參考文獻(xiàn)：
  1. Tsuzuki Y, et al. J Med Chem. 2004, 47(8), 2097-2109. 2. Hoch U, et al. Cancer Chemother Pharmacol. 2009, 64(1), 53-65.

• 溶解性： Soluble  in  DMSO

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	2.284 ml	11.418 ml	22.836 ml
  5 mM	0.457 ml	2.284 ml	4.567 ml
  10 mM	0.228 ml	1.142 ml	2.284 ml
  50 mM	0.046 ml	0.228 ml	0.457 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號：

本計算器可幫助您計算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *